Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Phase 3

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
B Acute Lymphoblastic Leukemia
Central Nervous System Leukemia
Testicular Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Clofarabine
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dasatinib
Drug: Dexamethasone
Drug: Etoposide
Drug: Doxorubicin Hydrochloride
Drug: Hydrocortisone Sodium Succinate
Drug: Leucovorin Calcium
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Thioguanine
Drug: Vincristine Sulfate
Drug: Prednisone
Radiation: Radiation Therapy

First Posted Date: 2016-08-30

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5949

Registration Number: NCT02883049

Locations: 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 236 locations

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Biological: Inotuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2016-08-24

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT02877303

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids

Conditions: Glucocorticoid

Interventions: Drug: Prednisone

First Posted Date: 2016-08-19

Last Posted Date: 2016-08-19

Lead Sponsor: Rambam Health Care Campus

Target Recruit Count: 20

Registration Number: NCT02872584

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Apalutamide
Drug: Abiraterone
Drug: ADT
Drug: Prednisone

First Posted Date: 2016-08-15

Last Posted Date: 2021-07-07

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 128

Registration Number: NCT02867020

Locations: 🇧🇷
Beneficiencia Portuguesa de São Paulo/Hospital São José, São Paulo, Brazil
🇧🇷
Hospital Erasto Gaertner, Curitiba, Paraná, Brazil
🇧🇷
IBCC, São Paulo, Brazil

and more 11 locations

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Phase 4

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Thalidomide
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Cisplatin
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2016-08-08

Last Posted Date: 2019-06-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 55

Registration Number: NCT02858804

Locations: 🇨🇳
Shuhua Yi, Tianjin, China

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Phase 2

Terminated

Conditions: Transformed Lymphoma / DLBCL
Diffuse, Large B-Cell, Lymphoma
Follicular Lymphoma, Grade 3b

Interventions: Drug: denintuzumab mafodotin
Drug: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2016-08-04

Last Posted Date: 2019-03-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 24

Registration Number: NCT02855359

Locations: 🇵🇷
Ponce Medical School Foundation, Ponce, Puerto Rico
🇺🇸
Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

and more 32 locations

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Phase 2

Completed

Conditions: Stage III Prostate Cancer AJCC v7
Stage IV Prostate Cancer AJCC v7
Stage III Prostate Adenocarcinoma AJCC v7
Stage IV Prostate Adenocarcinoma AJCC v7